ANIP Q1 2025 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$197M+43.4% YoY

Gross Profit

$124M62.9% margin

Operating Income

$26M13.3% margin

Net Income

$16M8.0% margin

EPS (Diluted)

$0.69

QoQ Revenue Growth

+3.4%

Cash Flow

Operating Cash Flow

$35M

Free Cash Flow

$15M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$849M

Stockholders' Equity

$443M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$197M	$137M	+43.4%
Gross Profit	$124M	$88M	+40.6%
Operating Income	$26M	$20M	+29.0%
Net Income	$16M	$18M	-13.9%

Revenue Segments

Total Sales of Generics and Other

$103M52%

Sales of rare disease pharmaceutical products

$69M35%

Sales of Established Brands

$25M13%